323 related articles for article (PubMed ID: 17668426)
21. [Molecular imaging of tumor blood vessels].
Tilki D; Singer B; Seitz M; Stief CG; Ergün S
Urologe A; 2007 Sep; 46(9):1266-71. PubMed ID: 17639291
[TBL] [Abstract][Full Text] [Related]
22. Angiogenesis as a strategic target for prostate cancer therapy.
Li Y; Cozzi PJ
Med Res Rev; 2010 Jan; 30(1):23-66. PubMed ID: 19536866
[TBL] [Abstract][Full Text] [Related]
23. LHT7, a chemically modified heparin, inhibits multiple stages of angiogenesis by blocking VEGF, FGF2 and PDGF-B signaling pathways.
Chung SW; Bae SM; Lee M; Al-Hilal TA; Lee CK; Kim JK; Kim IS; Kim SY; Byun Y
Biomaterials; 2015 Jan; 37():271-8. PubMed ID: 25453957
[TBL] [Abstract][Full Text] [Related]
24. The role of vascular endothelial growth factor in kidney and prostate cancer.
Delongchamps NB; Peyromaure M
Can J Urol; 2007 Oct; 14(5):3669-77. PubMed ID: 17949520
[TBL] [Abstract][Full Text] [Related]
25. Expression of angiogenesis stimulators and inhibitors in human thyroid tumors and correlation with clinical pathological features.
Bunone G; Vigneri P; Mariani L; Butó S; Collini P; Pilotti S; Pierotti MA; Bongarzone I
Am J Pathol; 1999 Dec; 155(6):1967-76. PubMed ID: 10595926
[TBL] [Abstract][Full Text] [Related]
26. Oncogenes and tumor angiogenesis: the question of vascular "supply" and vascular "demand".
Rak J; Yu JL
Semin Cancer Biol; 2004 Apr; 14(2):93-104. PubMed ID: 15018893
[TBL] [Abstract][Full Text] [Related]
27. Combined therapy with direct and indirect angiogenesis inhibition results in enhanced antiangiogenic and antitumor effects.
Abdollahi A; Lipson KE; Sckell A; Zieher H; Klenke F; Poerschke D; Roth A; Han X; Krix M; Bischof M; Hahnfeldt P; Grone HJ; Debus J; Hlatky L; Huber PE
Cancer Res; 2003 Dec; 63(24):8890-8. PubMed ID: 14695206
[TBL] [Abstract][Full Text] [Related]
28. The tyrosine kinase inhibitor cediranib blocks ligand-induced vascular endothelial growth factor receptor-3 activity and lymphangiogenesis.
Heckman CA; Holopainen T; Wirzenius M; Keskitalo S; Jeltsch M; Ylä-Herttuala S; Wedge SR; Jürgensmeier JM; Alitalo K
Cancer Res; 2008 Jun; 68(12):4754-62. PubMed ID: 18559522
[TBL] [Abstract][Full Text] [Related]
29. [Angiogenesis and neoangiogenesis--the role in lung cancer and other tumors].
Swidzińska E; Naumnik W; Chyczewska E
Pneumonol Alergol Pol; 2006; 74(4):414-20. PubMed ID: 17427152
[No Abstract] [Full Text] [Related]
30. Sex steroid regulation of angiogenesis in breast tissue.
Dabrosin C
Angiogenesis; 2005; 8(2):127-36. PubMed ID: 16211362
[TBL] [Abstract][Full Text] [Related]
31. Trimming the Vascular Tree in Tumors: Metabolic and Immune Adaptations.
Allen E; Missiaen R; Bergers G
Cold Spring Harb Symp Quant Biol; 2016; 81():21-29. PubMed ID: 28396525
[TBL] [Abstract][Full Text] [Related]
32. A therapeutically relevant, 3,3'-diindolylmethane derivative NGD16 attenuates angiogenesis by targeting glucose regulated protein, 78kDa (GRP78).
Nayak D; Amin H; Rah B; Ur Rasool R; Sharma D; Gupta AP; Kushwaha M; Mukherjee D; Goswami A
Chem Biol Interact; 2015 May; 232():58-67. PubMed ID: 25794856
[TBL] [Abstract][Full Text] [Related]
33. Targeting tumor micro-environment for design and development of novel anti-angiogenic agents arresting tumor growth.
Gacche RN; Meshram RJ
Prog Biophys Mol Biol; 2013 Nov; 113(2):333-54. PubMed ID: 24139944
[TBL] [Abstract][Full Text] [Related]
34. Expression of vascular endothelial growth factor (VEGF) and VEGF receptors in tumor angiogenesis and malignancies.
Pradeep CR; Sunila ES; Kuttan G
Integr Cancer Ther; 2005 Dec; 4(4):315-21. PubMed ID: 16282508
[TBL] [Abstract][Full Text] [Related]
35. [Tumor inhibitory factors in urologic malignancies].
Uemura H
Hinyokika Kiyo; 2008 Jan; 54(1):49-52. PubMed ID: 18260361
[TBL] [Abstract][Full Text] [Related]
36. [Angiogenesis--principles and significance in urologic tumors].
Strohmeyer D; Strohmeyer T
Urologe A; 1996 Sep; 35(5):357-62. PubMed ID: 8999626
[TBL] [Abstract][Full Text] [Related]
37. Endoglin for tumor imaging and targeted cancer therapy.
Paauwe M; ten Dijke P; Hawinkels LJ
Expert Opin Ther Targets; 2013 Apr; 17(4):421-35. PubMed ID: 23327677
[TBL] [Abstract][Full Text] [Related]
38. Effect of MDM2 and vascular endothelial growth factor inhibition on tumor angiogenesis and metastasis in neuroblastoma.
Patterson DM; Gao D; Trahan DN; Johnson BA; Ludwig A; Barbieri E; Chen Z; Diaz-Miron J; Vassilev L; Shohet JM; Kim ES
Angiogenesis; 2011 Sep; 14(3):255-66. PubMed ID: 21484514
[TBL] [Abstract][Full Text] [Related]
39. YC-1 [3-(5'-hydroxymethyl-2'-furyl)-1-benzyl indazole] inhibits endothelial cell functions induced by angiogenic factors in vitro and angiogenesis in vivo models.
Pan SL; Guh JH; Peng CY; Wang SW; Chang YL; Cheng FC; Chang JH; Kuo SC; Lee FY; Teng CM
J Pharmacol Exp Ther; 2005 Jul; 314(1):35-42. PubMed ID: 15784655
[TBL] [Abstract][Full Text] [Related]
40. Angiogenesis inhibitors in the treatment of prostate cancer.
Adesunloye BA; Karzai FH; Dahut WL
Chem Immunol Allergy; 2014; 99():197-215. PubMed ID: 24217611
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
